

JAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review

Tyler D. Hernandez,¹ Nicholas J. Culotta,¹ and Christopher J. Haas¹

¹ Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans 70112, United States.

Correspondence should be addressed to Tyler D. Hernandez; thern2@lsuhsc.edu

Abstract

Hidradenitis suppurativa (HS) is a debilitating inflammatory disorder that commonly manifests with lifelong recurrence of symptoms. Despite progress in HS management, effective treatment modalities remain scarce. This systematic review aims to examine the efficacy and safety of Janus kinase (JAK) inhibitors in treating HS. A comprehensive literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted. Inclusion criteria allowed for case reports, clinical trials, proof-of-concept studies, and cohort studies that assessed the outcomes of JAK inhibitor treatment in HS patients. 344 patients across ten studies qualified under these criteria, exploring various JAK inhibitors such as abrocitinib, baricitinib, tofacitinib, upadacitinib, and povorcitinib. The results reveal encouraging clinical outcomes, with significant alleviation of HS symptoms and improved quality of life in 48% of patients and only a 2.6% occurrence of clinically significant adverse events observed. Continued longitudinal research is essential to verify the sustained effectiveness and safety of JAK inhibitors in the treatment of HS.